BiotechTube
ISA Pharmaceuticals

ISA Pharmaceuticals

Leiden, Netherlands· Est.
isa-pharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $75M

Overview

ISA Pharmaceuticals is a clinical-stage biotech leveraging its proprietary synthetic long peptide (SLP) platform to create immunotherapies targeting cancers and persistent viral infections. The company's lead programs focus on HPV-related cancers and a therapeutic vaccine for chronic hepatitis B. While still pre-revenue, ISA has established key partnerships with major pharmaceutical companies to advance its pipeline and validate its platform technology.

OncologyInfectious Diseases

Technology Platform

Synthetic Long Peptide (SLP®) platform designed to induce potent and specific CD4+ and CD8+ T-cell responses against defined tumor or viral antigens.

Funding History

2
Total raised:$75M
Series C$40M
Series B$35M

Opportunities

The large, underserved markets for HPV-related cancers and chronic hepatitis B present multi-billion dollar opportunities for effective immunotherapies.
The validated partnership with Regeneron provides significant non-dilutive funding and development expertise for the lead oncology program.
The SLP platform has potential for expansion into other viral infections and cancers with well-defined antigens.

Risk Factors

High clinical development risk remains, as later-stage trials for ISA101b and ISA104 could fail on efficacy or safety.
The company is dependent on the successful execution of its partnership with Regeneron.
Intense competition from other immunotherapy modalities (mRNA, cell therapy) and large pharmaceutical companies poses a significant market threat.

Competitive Landscape

ISA competes in the crowded therapeutic vaccine and immunotherapy space. In HPV oncology, competitors include companies developing checkpoint inhibitors, adoptive cell therapies, and other vaccine modalities. In HBV, the competitive field includes antiviral drug developers, RNAi/siRNA therapies, and other immunotherapeutic approaches from major global pharma. ISA's differentiation lies in its specific SLP technology's safety profile and ability to induce broad T-cell responses.

More companies in Biologics / Biosimilars →More companies in Netherlands →